ArticleStroke (Hoboken, N.J.)2024
Comparison of nBCA and Onyx for Embolization of Spinal Dural Arteriovenous Fistulas.
Article in Stroke (Hoboken, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Safety and Efficacy of Vascular Embolization with N-Butyl Cyanoacrylate-Lipiodol Mixture: A Systematic Literature Review and Meta-Analysis of 8996 Patients.Cardiovascular and interventional radiology · 2026Review
- Spinal arteriovenous fistulas supplied by branches of internal iliac artery: clinical features and endovascular treatment outcomes.Acta neurochirurgica · 2026Article
- Case Report: Diagnostic anchoring in spinal dural arteriovenous fistula: a case-based analysis of clinical-radiological mismatch and delayed recognition.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endovascular embolization can effectively treat spinal dural arteriovenous fistulas (SDAVFs). One factor limiting the success and durability of endovascular treatments is reliably casting and occluding the draining vein. We sought to compare the efficacies of n-butyl-2-cyanoacrylate (nBCA) and Onyx in the treatment of SDAVFs. Methods: We retrospectively analyzed patients with SDAVFs treated with endovascular embolization for whether a "durable cure" was achieved, defined as complete obliteration, clinical improvement, and sustained radiologic cure on follow-up. We compared the outcomes of patients treated with Onyx to those treated with nBCA. Results: A total of 40 embolizations for SDAVFs were performed in 38 patients. All patients were treated exclusively with liquid embolysates: Onyx alone (n = 22), nBCA alone (n = 16), or nBCA and Onyx combined (n = 2). For 45% (10/22) of patients treated with Onyx only, complete obliteration of the fistula with casting of the vein was not achieved. These patients were referred for microsurgical ligation. For all 16 patients treated with nBCA only, complete obliteration of the fistula was achieved. All 16 patients exhibited a durable cure compared with 11 of 22 patients (50%) in the Onyx-only group ( Conclusion: nBCA may be superior to Onyx for the embolization of SDAVFs. nBCA embolization is safe and effective for a subset of SDAVFs. Prospective studies comparing SDAVF treatment strategies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.